These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24612173)

  • 1. The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer.
    Boyle DP; McArt DG; Irwin G; Wilhelm-Benartzi CS; Lioe TF; Sebastian E; McQuaid S; Hamilton PW; James JA; Mullan PB; Catherwood MA; Harkin DP; Salto-Tellez M
    Histopathology; 2014 Sep; 65(3):340-52. PubMed ID: 24612173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
    Fernández-Cuesta L; Oakman C; Falagan-Lotsch P; Smoth KS; Quinaux E; Buyse M; Dolci MS; Azambuja ED; Hainaut P; Dell'orto P; Larsimont D; Francis PA; Crown J; Piccart-Gebhart M; Viale G; Leo AD; Olivier M
    Breast Cancer Res; 2012 May; 14(3):R70. PubMed ID: 22551440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world Comparison of P53 Immunohistochemistry and TP53 Mutation Analysis Using Next-generation Sequencing.
    Lee H; Cho YA; Kim DG; Son JY; Cho EY
    Anticancer Res; 2024 Sep; 44(9):3983-3994. PubMed ID: 39197898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.
    Li X; Chen X; Wen L; Wang Y; Chen B; Xue Y; Guo L; Liao N
    Thorac Cancer; 2020 Jul; 11(7):1861-1868. PubMed ID: 32412177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined p53 and Bcl2 Immunophenotypes in Prognosis of Vietnamese Invasive Breast Carcinoma: A Single Institutional Retrospective Analysis.
    Van Nguyen C; Nguyen QT; Vu HTN; Phung HT; Pham KH; Le RD
    Technol Cancer Res Treat; 2020; 19():1533033820983081. PubMed ID: 33357134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.
    Dobes P; Podhorec J; Coufal O; Jureckova A; Petrakova K; Vojtesek B; Hrstka R
    Oncol Rep; 2014 Oct; 32(4):1695-702. PubMed ID: 25051299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.
    Sjögren S; Inganäs M; Norberg T; Lindgren A; Nordgren H; Holmberg L; Bergh J
    J Natl Cancer Inst; 1996 Feb; 88(3-4):173-82. PubMed ID: 8632491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer.
    Feng X; Li H; Dean M; Wilson HE; Kornaga E; Enwere EK; Tang P; Paterson A; Lees-Miller SP; Magliocco AM; Bebb G
    Breast Cancer Res; 2015 May; 17(1):65. PubMed ID: 25935535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors.
    Dajti G; Serra M; Cisternino G; Ceccarelli C; Pellegrini A; Melina M; De Leo A; Santini D; Taffurelli M; Zanotti S
    Oncologist; 2024 May; 29(5):384-391. PubMed ID: 37995311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
    Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
    Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
    Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer.
    Kim KM; Ahn AR; Park HS; Jang KY; Moon WS; Kang MJ; Ha GW; Lee MR; Chung MJ
    BMC Cancer; 2022 Aug; 22(1):940. PubMed ID: 36045334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.
    Beenken SW; Grizzle WE; Crowe DR; Conner MG; Weiss HL; Sellers MT; Krontiras H; Urist MM; Bland KI
    Ann Surg; 2001 May; 233(5):630-8. PubMed ID: 11323501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study.
    Li FY; Wu SG; Zhou J; Sun JY; Lin Q; Lin HX; Guan XX; He ZY
    PLoS One; 2014; 9(2):e87264. PubMed ID: 24498305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
    Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
    Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.